Background
==========

The year 2020 is the year of COVID-19. The pandemic has affected 212 countries and territories around the globe and continues to ravage many. The US and many European and Asian countries felt the disease impact before India did. As per the Ministry of Health and Family welfare, the government of India statistics on 20th May 2020, 61,149 active cases of the novel Corona virus disease (COVID -19) caused by the SARS-COV-2 virus were reported in India. As many as 3,303 people had died of this disease in India \[[@ref1]\]. The pandemic continues to spread in India and has resulted in widespread, government-led, lockdown measures to curb rapid spread. Health resources have been redirected towards care of COVID-19 patients in many centres here.

Drastic changes in healthcare delivery along with a country wide travel and movement ban means that many patients suffering from other health problems, notably cancer, are unable to access healthcare. Initial reports from China, the country which originally reported the virus, have evidence pointing towards potentially adverse outcomes in cancer patients affected by COVID-19 \[[@ref2]\]. All these factors have led to a dramatic change in practice protocols for Gynaecologic cancer patients across the country. Organisations have issued guidelines, albeit based on limited evidence, that decisions regarding surgery or chemotherapy should be highly individualised. It has been suggested that clinicians should carefully consider the risks of COVID-19 infection during therapy and balance it with the risks of altering the prognosis of cancer due to delays in the treatment \[[@ref3]\]. Based on these changes, this study was designed to look into the changes in gynaecologic oncology practice across India during the COVID-19 pandemic.

Methods
=======

This national survey was conducted amongst healthcare professionals involved in the care of gynaecologic cancer patients, when the caseload started rising steadily in several parts of the country. It was conducted in the first week of May, 2020. An online questionnaire was designed using google docs (<https://docs.google.com>). The questionnaire had six sections---Introduction, General questions, Endometrial cancer, Ovarian cancer, Cervical cancer and Vulval cancer in that order. The answers were given in multiple choice format and some were open ended and descriptive. The content was aimed at analysing the changes in the management of the above mentioned gynaecologic cancers types.

The survey was sent online by email and through social media platforms to clinicians with contact details accessed through national and local professional organisations. Attempts to make it representative of the entire country included telephone conversations with heads of leading cancer institutions across all states and ensuring participation. Survey responses were downloaded and analysed using SPSS software (v.20.0 IBM corporation, USA). To test categorical data, Chi square or Fisher's Exact test was used. *p* value of \<0.05 was considered to be significant.

Results
=======

The total number of responses recorded was 153. Five responders had double entries. The duplicates were omitted bringing down the responses for final analysis to 148. Responses were received from 19 out of 29 states in India.

[Table 1](#table1){ref-type="table"} shows the participants in the survey and the general measures adopted during the pandemic. Most of the participants were from academic institutes (75.7%). Seventy seven percent of the participants were surgeons (including gynaecologic and surgical oncologists and gynaecologists doing gynaecologic cancer surgery) and the rest included medical and radiation oncologists who are involved in the care of gynaecologic cancer patients. Ninety six percent reported a decrease in clinical practice during this period with surgeries declining for 98% of the responders. Multidisciplinary tumour board meetings were discontinued in half the centres and when it was continued, 99% had made modification to switch to virtual platform or reduce the number of participants. PCR to detect active COVID-19 infection was done by most (84%) before start of the treatment. 93% of the surgeons used additional protective measures in the operating theatre but full personal protective equipment was used only by 4%. Forty-two percent of the surgeons used smoke evacuators during surgery.

[Table 2](#table2){ref-type="table"} shows the differences in practice between the government and non-government practitioners. The comparison shows that during the pandemic there was significant reduction in the surgical volume of the practitioners in government institutions compared to those practicing in private institutions.

There was an equal number of responses from doctors practicing in areas with high and low volumes of COVID-19. A comparison between high and low COVID-19 incident states showed that the reduction of gynaecologic cancer patient load was seen across the country ([Table 3](#table3){ref-type="table"}). Healthcare facilities had a drop in cancer patient volumes irrespective of the COVID-19 case load in their states.

With respect to the change in protocols for each gynaecologic cancer type, the results are as follows:

Endometrial cancer
------------------

Management of low risk, low-grade endometrial cancers was still predominantly surgical (86% offering hysterectomy). The rest were being managed by hormonal treatment. Most clinicians responded that delay of surgery could be done safely up to 6 weeks (73%). Regarding the management of advanced endometrial cancers, systemic chemotherapy was being offered by 46.9%. The surgery was being offered by about one third (36%) and 11.6% were offered upfront radiation therapy.

Lymphadenectomy forms an important part of endometrial cancer surgery. [Figure 1](#figure1){ref-type="fig"} gives the proportion and type of lymph node assessment that was being offered during surgery.

Ovarian cancer
--------------

Undiagnosed ovarian mass with high index of suspicion was likely to be managed by laparotomy by over a half of the clinicians. To avoid surgical risk, almost 30% suggested Neoadjuvant chemotherapy (NACT) following image guided biopsy of the mass. Regarding the safe interval for postponement of surgery in apparently early stage ovarian cancer, about 90% of the responses agreed that surgery should be offered within 6 weeks. Single or combination chemotherapy given for six cycles was still being preferred by almost 90% of the clinicians for early stage ovarian cancer.

For management of advanced stage ovarian cancer, neoadjuvant chemotherapy seemed to be the preferred option (93%). Seventy percent opted to operate after three cycles while the rest were giving up to four to six cycles of NACT. Almost 15% preferred to continue with maintenance chemotherapy or metronomic therapy or just close follow up after six cycles of chemotherapy to avoid surgery during the pandemic period.

Up to 95% of newly diagnosed ovarian cancer patients were likely to have their chemotherapy initiated within 6 weeks of diagnosis.

Cervical cancer
---------------

For early operable cervical cancer, 66% of the respondents agreed on open radical hysterectomy, while less than 10% were likely to choose minimal access surgery. About 9% of the clinicians opted for concurrent chemoradiation for management of early stage cervical cancers. Two thirds of the respondents had altered their radiation schedules following the COVID-19 situation.

[Figure 2](#figure2){ref-type="fig"} gives the responses obtained regarding post op adjuvant radiation therapy. The responses veered towards following pre-COVID-19 protocols of adjuvant radiation therapy for intermediate and high-risk factors by most.

Vulvar cancer
-------------

For early stage vulvar cancer, a radical vulvectomy with sentinel node mapping (33%) was the most preferred option. While vulvectomy would be offered by the rest, 21% would not offer a groin node dissection and 19% would offer a concomitant node dissection.

For advanced vulvar cancer, concurrent chemoradiation was the preferred option by 42%. Neoadjuvant chemotherapy or radiation therapy before surgery was preferred by 43%. Surgery in this setting was the least preferred option.

Discussion
==========

The impetus behind this survey came from the sense of uncertainty that loomed large in conversations between clinicians across an array of platforms including on social media groups. It appeared that opinions were extremely diverse and this probably reflected the state of medical practice in India which ranges from small private, non-academic institutions to internationally known government or private oncology institutions, some of them with state-of-the-art facilities. The conversations were heavily coloured by the scientific data that was trickling in from countries which were at the peak of the COVID-19 pandemic ahead of India. The evidence from these countries pointed towards a potentially adverse outcome for COVID-19 infections in patients with cancer with a high risk of requiring ICU care, ventilation requirement and potentially death \[[@ref2], [@ref3]\]. Coupled with this, the inability of patients to access healthcare facilities due to the national lockdown meant that healthcare delivery is likely to be affected in many parts of the country. While health experts believe that the peak is yet to be reached in India, we needed to see the impact of the pandemic on gynaecologic cancer care at this time point \[[@ref4]\].

It was apparent that healthcare delivery has been affected with more than 95% of the clinicians agreeing that the numbers of oncology outpatients and cancer surgeries had fallen to varying extents across the country. Few centres remained unaffected. For most patients, once diagnosed, it was highly likely that they would be offered the current standard of care treatment in all the cancer sites covered in this survey. The big change was seen in offering surgery on minimal access platforms for endometrial cancer. The reports of increased COVID-19 infection risk to the surgical team from aerosolised viral particles in pneumoperitoneum was probably a reason \[[@ref5]\]. The current evidence on the relative COVID-19 risks to the surgical team for MIS and conventional surgery seems to be unclear \[[@ref6]\]. However, considering the early recovery and reduced length of stay in MIS, it should be considered as a viable option. According to the SAGES guideline, consideration should be given to the possibility of viral contamination to staff during surgery whether open, laparoscopic or robotic and appropriate protective measures should be taken \[[@ref7]\].

While surgery may be possible if there is no disruption of routine clinical services, delay in surgery may be inevitable in many centres because of diversion of healthcare resources towards COVID-19 cases. There is some evidence that a delay in surgery of more than 6 weeks was associated with the worst overall survival for type 1 endometrial cancers, especially stage 1 and 2 \[[@ref8]\]. Keeping this in mind would be helpful when the time-lines for surgery are altered. Three fourths (75% approximately) of the respondents opined to operating within 6 weeks. Hormonal therapy was considered by 11% in this survey for treatment of early endometrial cancer. If a delay in surgery is inevitable it may be reasonable to offer systemic progesterone or intrauterine hormonal device \[[@ref9]\]. For high risk endometrial cancer, most of the respondents favoured lymph node dissection, pelvic with or without paraaortic dissection. While this is in agreement with pre COVID guidelines, the increased surgical time and its associated increased morbidity in the present circumstances need to be considered. Current recommendations bring up the role of sentinel node dissection in these patients in line with the MSKCC protocol to reduce surgical morbidity \[[@ref9], [@ref10]\].

Early cervical cancer may be treated by surgery or chemoradiation as found appropriate. It had been shown that a delay of more than 4 months may significantly worsen prognosis across all stages of cervical cancers \[[@ref11]\]. Hence, early and stage-appropriate treatment is more important than the modality of treatment, especially in this country with large cervical cancer volumes. While surgery seems more appropriate for early ovarian cancer, neoadjuvant chemotherapy that may be stretched to six cycles seems to be the recommendation for advanced ovarian cancers in the current pandemic situation \[[@ref8], [@ref10]\]. Most responses in this survey as described above seem to be in line with the current leading recommendations.

At present, it appears that the volume of cancer patients in centres across the country had reduced. This may lead to patients having delayed diagnosis and treatment and further lead to a possibility of presenting at more advanced and potentially incurable stages of disease in the near future. The hope is that easing of lockdown restrictions will enable patients to access healthcare facilities and enable timely treatment. The failure to do so will greatly increase the collateral damage of this unprecedented COVID-19 pandemic.

Conclusions
===========

This survey showed that there is a drop in the volume of cancer patients reaching treatment centres across India regardless of local COVID-19 volumes and the type of practice set up. While the management of endometrial cancers and cervical cancers was mostly unchanged, most cases of advanced ovarian cancer received neoadjuvant chemotherapy. Cervical cancer, when managed by chemoradiation, was likely to have altered radiation schedules.
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###### Details of the participants and general measures adopted during the COVID 19 pandemic.

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Question                                                                       Answer                           *N* (%)\            Not answered
                                                                                                                  (Total *n* = 148)   
  ------------------------------------------------------------------------------ -------------------------------- ------------------- --------------
  **General section**                                                                                                                 

  Practice setting                                                               Academic institute: Government   36 (24.3)           

  Academic institute: Private                                                    76 (51.4)                                            

  Non academic: Private                                                          34 (23.0)                                            

  Non academic: government hospital                                              2 (1.4)                                              

  Specialty                                                                      Gynaecologic Oncologist          74 (50.0)           

  Surgical Oncologist                                                            26 (17.6)                                            

  Medical Oncologist                                                             21 (14.2)                                            

  Radiation Oncologist                                                           12 (8.1)                                             

  Gynaecologist                                                                  15(10.1)                                             

  Gynaecological cancer patients seen per month (before the onset of COVID-19)   \<50                             84 (56.8)           

  51--100                                                                        30 (20.3)                                            

  101--250                                                                       14 (9.5)                                             

  \>250                                                                          20 (13.5)                                            

  Gynaecological cancer surgeries per month (before the onset of COVID-19)       \<10                             41 (27.7)           28 (18.9)

  11--20                                                                         38 (25.7)                                            

  21--30                                                                         18 (12.2)                                            

  \>30                                                                           23 (15.5)                                            

  States with high volume of confirmed COVID--19 cases                           \>3,500                          75 (50.7)           

  ≤3,500                                                                         73 (49.3)                                            

  Decrease in practice after COVID 19 Pandemic                                   No                               6 (4.1)             

  Yes                                                                            142 (95.9)                                           

  Decreased practice in percentage                                               No surgery                       3 (2.0)             1 (0.7)

  \<10% of usual volume                                                          39 (26.4)                                            

  About 1/4th of usual volume                                                    58 (39.2)                                            

  About 1/2 of usual volume                                                      30 (20.3)                                            

  About 3/4th of usual volume                                                    14 (9.5)                                             

  No change                                                                      3 (2.0)                                              

  MDTB in COVID 19 pandemic                                                      Not conducted                    72 (48.6)           

  Conducted                                                                      76 (51.4)                                            

  Mode of MDTB if Yes                                                            Virtual tumour board             54 (36.5)           60 (40.5)

  Tumour board with \<5 participants                                             23 (15.5)                                            

  Tumour board with 6--10 participants                                           9 (6.1)                                              

  As before                                                                      2 (1.4)                                              

  RT PCR before cancer treatment                                                 Yes                              60 (40.5)           

  Only selected high risk patients as per Institutional policy                   64 (43.2)                                            

  COVID 19 testing not mandatory                                                 24 (16.2)                                            

  Additional precautions in view of COVID 19 pandemic                            No                               13 (8.8)            

  Yes                                                                            135 (91.2)                                           

  Various additional precaution                                                  No precaution                    1 (0.7)             25 (16.9)

  N95 mask and visor                                                             65 (44)                                              

  Full PPE                                                                       51 (34.4)                                            

  Full PPE and reduce personnel in OT                                            6 (4)                                                

  Smoke evacuator during surgery                                                 No                               80 (54)             5 (3.4)

  Yes                                                                            63 (42.6)                                            
  --------------------------------------------------------------------------------------------------------------------------------------------------

###### Differences in practice between Government and non government practitioners.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *n* = 148                                                                                                                                   Government Hospital (*n* = 38)\   Private Hospital\   *p* value
                                                                                                                                              *n* (%)                           (*n* = 110)\        
                                                                                                                                                                                *n* (%)             
  ------------------------------------------------------------------------ ------------------------------------------------------------------ --------------------------------- ------------------- --------------
  **General section**                                                                                                                                                                               

  Gynaecological cancer patients seen per month before COVID-19 pandemic   \<50                                                               14 (36.8)                         70 (63.6)           **\<0.0001**

  51--100                                                                  10 (26.3)                                                          20 (18.2)                                             

  101--250                                                                 2 (5.3)                                                            12 (10.9)                                             

  \>250                                                                    12 (31.6)                                                          8 (7.3)                                               

  Gynaecological cancer surgeries per month before COVID-19 pandemic       \<10                                                               9 (24.3)                          32 (38.6)           0.191

  11--20                                                                   11 (29.7)                                                          27 (32.5)                                             

  21--30                                                                   6 (16.2)                                                           12 (14.5)                                             

  \>30                                                                     11 (29.7)                                                          12 (14.5)                                             

  No of responses according to COVID volume                                High volume of COVID cases\                                        17 (44.7)                         58 (52.7)           0.396
                                                                           \>3,500 cases during survey\                                                                                             
                                                                           ; 5 states (Maharashtra, Gujarat, Tamil Nadu, Delhi, Rajasthan).                                                         

  Low volume of COVID cases\                                               21 (55.3)                                                          52 (47.3)                                             
  ≤3,500 cases during survey                                                                                                                                                                        

  Decrease in practice after COVID 19 Pandemic                             No                                                                 1 (2.6)                           5 (4.5)             0.606

  Yes                                                                      37 (97.4)                                                          105 (95.5)                                            

  Decreased practice in percentage                                         No surgery                                                         3 (8.1)                           0 (0)               **0.016**

  \<10% of usual volume                                                    13 (35.1)                                                          26 (23.6)                                             

  About 1/4th of usual volume                                              13 (35.1)                                                          45 (40.9)                                             

  About 1/2 of usual volume                                                7 (18.9)                                                           23 (20.9)                                             

  About 3/4th of usual volume                                              1 (2.7)                                                            13 (11.8)                                             

  No change                                                                0 (0)                                                              3 (2.7)                                               

  MDTB in COVID 19 pandemic                                                No                                                                 27 (71.1)                         45 (40.9)           **0.001**

  Yes                                                                      11 (28.9)                                                          65 (59.1)                                             

  Mode of MDTB if Yes                                                      Virtual tumour board                                               6 (42.9)                          48 (64.9)           **0.028**

  Tumour board with \<5 participants                                       8 (57.1)                                                           15 (20.3)                                             

  Tumour board with 6-10 participants                                      0 (0)                                                              9 (12.2)                                              

  As before                                                                0 (0)                                                              2 (2.7)                                               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Difference in practice according to the Volume of COVID-19.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *n*=148                                                                               Practice in states with confirmed COVID cases \>3500 (*n*=75)\   Practice in states with confirmed COVID cases ≤3500 (*n*=73)\   *p* value
                                                                                        *n*(%)                                                           *n*(%)                                                          
  -------------------------------------------------------------- ---------------------- ---------------------------------------------------------------- --------------------------------------------------------------- -----------
  **General Section**                                                                                                                                                                                                    

  Decreased practice in percentage                               No surgery             1(1.4)                                                           2(2.7)                                                          0.068

  \<10% of usual volume                                          24(32.4)               15(20.5)                                                                                                                         

  About 1/4 of usual volume                                      33(44.6)               25(34.2)                                                                                                                         

  About 1/2 of usual volume                                      12(16.2)               18(24.7)                                                                                                                         

  About 3/4 of usual volume                                      4(5.4)                 10(13.7)                                                                                                                         

  No change                                                      0(0)                   3(4.1)                                                                                                                           

  Mode of MDTB                                                   Virtual tumour board   36(76.6)                                                         18(43.9)                                                        0.004

  Tumour board with \<5 participants                             10(21.3)               13(31.7)                                                                                                                         

  Tumour board with 6-10 participants                            1(2.1)                 8(19.5)                                                                                                                          

  As before                                                      0(0)                   2(4.9)                                                                                                                           

  RT PCR before cancer treatment                                 Yes                    36(48)                                                           24(32.9)                                                        0.165

  Only selected high-risk patients as per institutional policy   29(38.7)               35(47.9)                                                                                                                         

  COVID 19 testing not mandatory                                 10(13.3)               14(19.2)                                                                                                                         
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
